Patents by Inventor Ryan A. Shenvi

Ryan A. Shenvi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11512075
    Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 29, 2022
    Assignee: The Scripps Research Institute
    Inventors: Ryan Shenvi, Jeremy Roach, Yusuke Sasano, Laura Bohn, Cullen Schmid
  • Patent number: 11351147
    Abstract: The present disclosure relates to concise processes for making (?)-picrotoxinin (1, PXN) and 5-methyl-picrotoxinin (20, 5MePXN), and to 5MePXN, its pharmaceutical compositions, and its method of use for inhibiting GABAA receptor.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 7, 2022
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Steven W. M. Crossley, Guanghu Tong, Michael Lambrecht, Ryan Shenvi
  • Publication number: 20220040147
    Abstract: The present disclosure relates to concise processes for making (?)-picrotoxinin (1, PXN) and 5-methyl-picrotoxinin (20, 5MePXN), and to 5MePXN, its pharmaceutical compositions, and its method of use for inhibiting GABAA receptor.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 10, 2022
    Inventors: Steven W. M. Crossley, Guanghu Tong, Michael Lambrecht, Hannah Burdge, Ryan Shenvi
  • Publication number: 20200131162
    Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 30, 2020
    Inventors: Ryan Shenvi, Jeremy Roach, Yusuke Sasano, Laura Bohn, Cullen Schmid
  • Patent number: 8642766
    Abstract: An in vitro synthesis of (+) cortistatin A from readily available precursors is disclosed, as are the syntheses of related 17-aryl substituted compounds, the 17-aryl substituted compounds themselves and novel compounds useful in their preparation.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: February 4, 2014
    Inventors: Ryan A. Shenvi, Carlos A. Guerrero, Jun Shi, Chuang-Chuang Li, Phil S. Baran
  • Publication number: 20110060140
    Abstract: An in vitro synthesis of (+) cortistatin A from readily available precursors is disclosed, as are the syntheses of related 17-aryl substituted compounds, the 17-aryl substituted compounds themselves and novel compounds useful in their preparation.
    Type: Application
    Filed: April 30, 2009
    Publication date: March 10, 2011
    Inventors: Ryan A. Shenvi, Carlos A. Guerrero, Jun Shi, Chuang-Chuang Li, Phil S. Baran